SEHK:3692Pharmaceuticals
Hansoh Pharmaceutical Group SEHK 3692 Valuation Check After Ameile First Line Lung Cancer Approval
Hansoh Pharmaceutical Group (SEHK:3692) has just received Chinese NMPA approval to expand lung cancer drug Ameile’s use as a first line option in combination therapy for specific EGFR mutated NSCLC patients.
See our latest analysis for Hansoh Pharmaceutical Group.
The Ameile update comes after a reshuffle of Hansoh Pharmaceutical Group’s board and committees in late December 2025. The latest 1-day share price return of 2.11% at HK$41.6 sits within a year-to-date share price return of 14.16%...